A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non‑Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

  • Cancer
  • Lung Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Country
  • United States
Trial Identifier:

NCT02927301 ML39236

  • City of Hope Comprehensive Cancer Center

    91010DuarteUnited States
  • UCLA Cancer Center

    90404Santa MonicaUnited States
  • University Of Colorado

    80045AuroraUnited States
  • Yale Cancer Center

    06510New HavenUnited States
  • Moffitt Cancer Center

    33612TampaUnited States
  • Emory University; Winship Cancer Institute

    30322AtlantaUnited States
  • Dana Farber Cancer Institute; Brigham and Womens Hospital

    02115BostonUnited States
  • Mass General/North Shore Cancer

    01923DanversUnited States
  • Karmanos Cancer Inst; Hematology/Oncology

    48201DetroitUnited States
  • Washington University; Wash Uni. Sch. Of Med

    63105St. LouisUnited States
  • Dartmouth Hitchcock Medical Center

    03756LebanonUnited States
  • Memorial Sloan Kettering - Monmouth

    07748middletown-townshipUnited States
  • Memorial Sloan Kettering Cancer Center - Commack

    11725CommackUnited States
  • Memorial Sloan Kettering Cancer Center at Westchester

    10604New YorkUnited States
  • New York University Medical Center

    10036New YorkUnited States
  • Memorial Sloan Kettering - Basking Ridge

    10065New YorkUnited States
  • Memorial Sloan Kettering Cancer Center

    10065New YorkUnited States
  • Memorial Sloan Kettering Nassau

    11553UniondaleUnited States
  • The Ohio State University Comprehensive Cancer Center

    43210ColumbusUnited States
    Show trial locations

    The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

    The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

    Results Disclaimer

    Trial Summary

    This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC). Neoadjuvant therapy consisted of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy consisted of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy. All participants who undergo surgery entered a surveillance period, which consisted of standardized blood sample collection and Chest CT Scans, for up to 2 years. All participants were monitored for disease recurrence and survival for up to 3 years after last dose of study drug.

    Genentech, Inc. Sponsor
    Phase 2 Phase
    NCT02927301, ML39236 Trial Identifier
    Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Treatments
    Non-Small Cell Lung Cancer Condition
    Official Title

    A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer

    Eligibility Criteria

    All Gender
    ≥ 18 Years Age
    No Healthy Volunteers
    Inclusion Criteria
    • Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC
    • Adequate pulmonary and cardiac function
    • Available biopsy of primary tumor with adequate samples
    • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    Exclusion Criteria
    • NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease
    • Any prior therapy for lung cancer within 3 years.
    • Prior treatment with anti-PD-1 or PD-L1 therapies
    • History or risk of autoimmune disease

    Clinical Research Explained

    Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

    Find out now